{"id":"NCT02434497","sponsor":"AstraZeneca","briefTitle":"A Study to Evaluate the Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia","officialTitle":"An Open-Label Long-Term Extension to the Randomized, Double-blind, Placebo-controlled, Multi-center, Cross-over Study of Rosuvastatin in Children and Adolescents (Aged 6 to <18 Years) With Homozygous Familial Hypercholesterolemia (HoFH)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-06-06","primaryCompletion":"2016-11-17","completion":"2016-11-17","firstPosted":"2015-05-05","resultsPosted":"2018-02-27","lastUpdate":"2018-02-27"},"enrollment":9,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Homozygous Familial Hypercholesterolemia (HoFH)"],"interventions":[{"type":"DRUG","name":"Rosuvastatin 20mg","otherNames":[]}],"arms":[{"label":"Single Arm","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to evaluate the safety of Rosuvastatin in Children and Adolescents with Homozygous Familial Hypercholesterolemia.","primaryOutcome":{"measure":"The Number of Participants Who Experianced Adverse Events and Serious Adverse Events","timeFrame":"96 weeks","effectByArm":[{"arm":"Full Analysis Set","deltaMin":5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":6,"countries":["Belgium","Canada","Denmark","Israel","Malaysia","Taiwan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":9},"commonTop":["Nasopharyngitis","Otitis externa","Upper respiratory tract infection","Dysuria","Proteinuria"]}}